PURPOSE: ABT-751 is an oral antimitotic agent that binds to the colchicine site on beta-tubulin. A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias. STUDY DESIGN: Thirty-two patients were treated: nine with 100 (n = 3), 125 (n = 3), or 150 mg/m(2) (n = 3) of ABT-751 given orally once daily for 7 days every 3 weeks and 23 with 75 (n = 3), 100 (n = 3), 125 (n = 5), 150 (n = 5), 175 (n = 3), or 200 mg/m(2) (n = 4) of ABT-751 given orally once daily for 21 days every 4 weeks. Consenting patients had pharmacogenetic sampling and enumeration of circulating endothelial cells (CEC). RESULTS: Dose-limiting toxicity consisted of ileus in one patient at 200 mg/m(2), with a subsequent patient developing grade 2 constipation at the same dose level. One patient with relapsed acute myelogenous leukemia achieved a complete remission that was sustained for 2 months. Four other patients had transient hematologic improvements, consisting of a decrease in peripheral blood blasts and improvements in platelet counts. CEC number was reduced in three patients with a concomitant reduction in peripheral blasts. A previously undescribed nonsynonymous single nucleotide polymorphism, encoding Ala(185)Thr, was identified in exon 4 of the beta-tubulin gene, TUBB, in three other patients. The recommended phase 2 dose in hematologic malignancies is 175 mg/m(2) daily orally for 21 days every 4 weeks. CONCLUSION: Further assessment of ABT-751, especially in combination with other agents, in patients with acute leukemias is warranted.
PURPOSE:ABT-751 is an oral antimitotic agent that binds to the colchicine site on beta-tubulin. A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias. STUDY DESIGN: Thirty-two patients were treated: nine with 100 (n = 3), 125 (n = 3), or 150 mg/m(2) (n = 3) of ABT-751 given orally once daily for 7 days every 3 weeks and 23 with 75 (n = 3), 100 (n = 3), 125 (n = 5), 150 (n = 5), 175 (n = 3), or 200 mg/m(2) (n = 4) of ABT-751 given orally once daily for 21 days every 4 weeks. Consenting patients had pharmacogenetic sampling and enumeration of circulating endothelial cells (CEC). RESULTS: Dose-limiting toxicity consisted of ileus in one patient at 200 mg/m(2), with a subsequent patient developing grade 2 constipation at the same dose level. One patient with relapsed acute myelogenous leukemia achieved a complete remission that was sustained for 2 months. Four other patients had transient hematologic improvements, consisting of a decrease in peripheral blood blasts and improvements in platelet counts. CEC number was reduced in three patients with a concomitant reduction in peripheral blasts. A previously undescribed nonsynonymous single nucleotide polymorphism, encoding Ala(185)Thr, was identified in exon 4 of the beta-tubulin gene, TUBB, in three other patients. The recommended phase 2 dose in hematologic malignancies is 175 mg/m(2) daily orally for 21 days every 4 weeks. CONCLUSION: Further assessment of ABT-751, especially in combination with other agents, in patients with acute leukemias is warranted.
Authors: Tian Ma; Alexander D Fuld; James R Rigas; Anne E Hagey; Gary B Gordon; Ethan Dmitrovsky; Konstantin H Dragnev Journal: Chemotherapy Date: 2012-11-12 Impact factor: 2.544
Authors: Christopher L Morton; Edward G Favours; Kimberly S Mercer; Claire R Boltz; Jeri Carol Crumpton; Chandra Tucker; Catherine A Billups; Peter J Houghton Journal: Invest New Drugs Date: 2007-03-24 Impact factor: 3.850
Authors: A L Risinger; C D Westbrook; A Encinas; M Mülbaier; C M Schultes; S Wawro; J D Lewis; B Janssen; F J Giles; S L Mooberry Journal: J Pharmacol Exp Ther Date: 2010-12-09 Impact factor: 4.030
Authors: Federico Innocenti; Jacqueline Ramírez; Jennifer Obel; Julia Xiong; Snezana Mirkov; Yi-Lin Chiu; David A Katz; Robert A Carr; Wei Zhang; Soma Das; Araba Adjei; Ann M Moyer; Pei Xian Chen; Andrew Krivoshik; Diane Medina; Gary B Gordon; Mark J Ratain; Leonardo Sahelijo; Richard M Weinshilboum; Gini F Fleming; Anahita Bhathena Journal: Pharmacogenet Genomics Date: 2013-07 Impact factor: 2.089
Authors: Elizabeth Fox; John M Maris; Susan L Cohn; Wendy Goodspeed; Anne Goodwin; Marie Kromplewski; Diane Medina; Hao Xiong; Andrew Krivoshik; Brigitte Widemann; Peter C Adamson; Frank M Balis Journal: Cancer Chemother Pharmacol Date: 2010-01-01 Impact factor: 3.333